Qinecsa Solutions (Qinecsa), specialists in technology-led end-to-end pharmacovigilance solutions, has announced its acquisition of Insife ApS (Insife), a Danish software, technology and consultancy firm specialising in developing pharmacovigilance platforms.
This acquisition is in alignment with Qinecsa’s vision, playing a crucial role in the company’s pursuit to become the leading provider of digital pharmacovigilance solutions.
Through advanced platforms like Reportum and CVW, Qinecsa empowers life science companies to capture, manage and evaluate drug safety data with efficiency and accuracy throughout the drug life cycle.
The HALOPV platform developed by Insife is considered a safety database with multivigilance capabilities and more, as it covers the end-to-end management of PV processes.
HALOPV is available as an enterprise-grade technology, as well as in a multi-tenant SaaS offering for cost-effective uses. In addition, Insife’s global regulatory intelligence for pharmacovigilance (GRIP) club is a unique combination of technology, multi-sourced intelligence and networking, specifically for pharmacovigilance professionals involved in identifying, assessing and implementing requirements.
The acquisition of Insife by Qinecsa represents a strategic move to further strengthen Qinecsa’s position as the leading provider of pharmacovigilance solutions, and technologies.
John Gillie, CEO of Qinecsa Solutions, stated: “By integrating Insife’s automation technology, specialised knowledge and consultancy services into our offerings, we are poised to deliver even greater value and support to our customers globally.”
